Cytotoxic RuII-p-cymene complexes of an anthraimidazoledione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation

RuII-(η6-p-cymene) complexes of anthraimidazoldione (PAIDH) based ligand bearing the formula [RuII(η6-p-cymene)(PAIDH)(X)]+ (where, X = Cl, Br and I) showed excellent in vitro antiproliferative activity (IC50 range 1-2 μM) against hepatocellular carcinoma (HepG2), human pancreatic carcinoma (MIA PaCa-2) and triple negative human metastatic breast adenocarcinoma (MDA-MB-231). The ESI-MS and 1H NMR data show that the complexes are stable in aqueous solution at pH 7.4 (4 mM NaCl) with less than 10% hydrolysis in 24 h. However, when the coordinated halide is bromo (2) or iodo (3), the complex exchanges the halide with chloride in solution. The exchange is dependent on chloride concentration. Fastest chloride exchange was observed for the bromo complex 2 and slowest for the iodo complex 3 showing the higher kinetic inertness of the latter. Complex 3 exhibits the weakest interaction with glutathione (GSH) and 9-ethylguanine (9-EtG) in the series. ESI-MS studies of a 20% methanolic solution of 3 in 4 mM aqueous NaCl showed 80% intact complex even after 24 h of incubation with 9-EtG or GSH. 1-3 show similar in vitro cytotoxicity profile, but based on combined results from solution stability and cytotoxicity, the iodo complex 3 seems to be the best one in the series. There is no deterioration of toxicity under hypoxia or by induction of GSH in HepG2 cells. The low cytotoxicity of the complexes against difficult to treat triple negative breast carcinoma viz. MDA-MB-231 in vitro (IC50 = 1.5 ± 0.1 μM) is very encouraging, compared with cytotoxicity of clinical drug cisplatin (IC50 = 37.2 ± 2.5 μM). The complexes can alter mitochondrial membrane potential, arrest the cell cycle in G0/G1 phase and kill cells via apoptosis. They inhibit migration of the metastatic MDA-MB-231 cells at IC20 dose.

Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates

Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes with anticancer properties are reviewed.

DNA interaction and photocleavage properties of Ru (II) complexes [Ru(bpy)₂(pibi)]²⁺ and [Ru(phen)₂(pibi)]²⁺

A new asymmetry ligand pibi (pibi = 2-(pyridine-2-yl)-1-H-imidazo[4,5-f]benzo[d]imidazolone) and its ruthenium complexes with [Ru(L)2(pibi)](2+) (L = bpy (2, 2'-bipyridine), phen (1, 10-phenanthroline)), have been synthesized and characterized. The binding of two complexes with calf thymus DNA has been investigated by spectroscopic and viscosity measurement. The results indicate that both complexes can bind to CT-DNA through intercalative mode. Under irradiation at 365 nm, both complexes can partly promote the photocleavage of plasmid pBR322DNA. The low singlet oxygen generation abilities of the two complexes may be the factor for the low DNA photocleavage abilities.

Microwave-Assisted Synthesis of Ruthenium(II) Complexes with Trimethylsilylacetylene as Inhibitors against the Migration of Breast Cancer Cells

In the present study, two novel chiral ruthenium(ii) complexes with trimethylsilylacetylene (TMSA), Λ- and Δ-[Ru(bpy)2(p-TEPIP)](ClO4)2 (bpy = 2,2-bipyridine; p-TEPIP = 5-(2-(p-trimethylsilyl propargyl)-1H-imidazo[4,5-f][1,10] phenanthroline) (Λ-1 and Δ-1) were prepared using Sonogashira coupling reaction under microwave irradiation. We found that both Λ-1 and Δ-1 could inhibit the growth of highly metastatic human breast cancer cells (MDA-MB-231) with half-maximal inhibitory concentration (IC50) of 32.1 and 36.9 µM, respectively. Wound healing assay demonstrated that both isomers inhibited the migration of MDA-MB-231 cells. Both Λ-1 and Δ-1 compounds were found throughout the cell and were particularly enriched in the nucleus. Furthermore, we observed fragmentation of the nucleus leading to apoptosis. To conclude, it is clear that this type of chiral ruthenium(ii) complex with TMSA can induce apoptosis and thus inhibit the growth and migration of tumour cells.

The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes

Four ruthenium(ii) asymmetric complexes, [Ru(bpy)2(PAIDH)](2+) (bpy = 2,2'-bipyridine, PAIDH = 2-pyridyl-1H-anthra[1,2-d]imidazole-6,11-dione, ), [Ru(phen)2(PAIDH)](2+) (phen = 1,10-phenanthroline, ), [Ru(dmp)2(PAIDH)](2+) (dmp = 4,7-dimethyl-1,10-phenanthroline, ) and [Ru(dip)2(PAIDH)](2+) (dip = 4,7-diphenyl-1,10-phenanthroline, ), have been synthesized and characterized. These complexes displayed potent anti-proliferation activity against various cancer cell lines and had high selectivity between tumor cells and normal cells. HeLa cells exhibited the highest sensitivity to complex , accounting for the greatest cellular uptake. Complex was shown to accumulate preferentially in the mitochondria of HeLa cells and induced apoptosis via the mitochondrial pathway, which involved ROS generation, mitochondrial membrane potential depolarisation, and Bcl-2 and caspase family members activation. These results demonstrated that complex induced cancer cell apoptosis by acting on mitochondrial pathways.